Analyse Xenon Pharmaceuticals Inc. (XENE) — Kairos Score 62/100

À propos de Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Informations clés

🕴️ Activité des initiés (90 jours)

6 transactions — 2 achats et 3 ventes déclarés par les dirigeants de Xenon Pharmaceuticals Inc..

🏦 Hedge Funds

17 fonds institutionnels déclarent une position sur XENE dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur XENE.

• Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.